Quest Diagnostics announced the launch of the industry’s first molecular blood test for identifying kidney organ transplant rejection. The Renal Transplant Monitoring laboratory-developed test is designed to help physicians detect kidney failure weeks before conventional tests or clinical symptoms signify damage. The test may potentially improve patient care for kidney transplant patients while helping to lower healthcare costs associated with renal transplant failure.

Standard post-transplant monitoring involves lab testing of serum creatinine, a marker of renal function, and renal biopsy, a procedure which can cause bleeding and graft injury or loss. The new test is based on the RNA genetic markers forkhead box P3 (FoxP3), granzyme B (GZMB), and perforin (PRF1). Earlier detection of transplant rejection may spur interventions that help to improve the likelihood of graft survival.

For more information visit